These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23740237)

  • 1. The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.
    Plasencia Ch; Pascual-Salcedo D; Alcocer P; Bonilla MG; Villalba A; Peiteado D; Arribas F; Díez J; Lopez-Casla MT; Martín-Mola E; Balsa A
    Ann Rheum Dis; 2013 Nov; 72(11):1888-90. PubMed ID: 23740237
    [No Abstract]   [Full Text] [Related]  

  • 2. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB; Grunert VP; Hetland ML; Johansen JS; Rothfuss M; Palermo G; Essioux L; Klause U
    Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B; Cameron L; Ouellet M; White B
    J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C; Engstrand S; Sundqvist KG; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D; Plasencia C; Ramiro S; Nuño L; Bonilla G; Nagore D; Ruiz Del Agua A; Martínez A; Aarden L; Martín-Mola E; Balsa A
    Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.
    Dervieux T; Weinblatt ME; Kivitz A; Kremer JM
    Ann Rheum Dis; 2013 Jun; 72(6):908-10. PubMed ID: 23161901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the functional characteristics of antibodies to therapeutic anti-human tumor necrosis factor alpha monoclonal antibody.
    Yucel A; Aral AL; Basturk B; Karakus R; Aybay C; Aybay C
    Immunol Lett; 2007 Aug; 111(2):84-91. PubMed ID: 17618693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.
    Ducourau E; Mulleman D; Paintaud G; Miow Lin DC; Lauféron F; Ternant D; Watier H; Goupille P
    Arthritis Res Ther; 2011 Jun; 13(3):R105. PubMed ID: 21708018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.
    Kneepkens EL; Plasencia C; Krieckaert CL; Pascual-Salcedo D; van der Kleij D; Nurmohamed MT; López-Casla MT; Wieringa R; Rispens T; Wolbink G
    Ann Rheum Dis; 2014 Dec; 73(12):2217-9. PubMed ID: 25261580
    [No Abstract]   [Full Text] [Related]  

  • 13. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M; Rauch J; Armstrong M; Fitzcharles MA
    J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.
    Bingham SJ; Buch MH; Kerr MA; Emery P; Valadäo Barcelos AT
    Arthritis Rheum; 2004 Dec; 50(12):4072-3. PubMed ID: 15593202
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.
    Plasencia C; Pascual-Salcedo D; Nuño L; Bonilla G; Villalba A; Peiteado D; Díez J; Nagore D; del Agua AR; Moral R; Martin-Mola E; Balsa A
    Ann Rheum Dis; 2012 Dec; 71(12):1955-60. PubMed ID: 22563028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.